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Spinal cord injuries remain a critical issue in experimental and clinical research nowadays, and it is now well
accepted that the immune response and subsequent inflammatory reactions are of significant importance in
regulating the damage/repair balance after injury. The role of macrophages in such nervous system lesions now
becomes clearer and their contribution in the wound healing process has been largely described in the last few
years. Conversely, the contribution of neutrophils has traditionally been considered as detrimental and unfavorable
to proper tissue regeneration, even if there are very few studies available on their precise impact in spinal cord
lesions. Indeed, recent data show that neutrophils are required for promoting functional recovery after spinal cord
trauma. In this review, we gathered recent evidence concerning the role of neutrophils in spinal cord injuries but
also in some other neurological diseases, highlighting the need for further understanding the different mechanisms
involved in spinal cord injury and repair.
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According to the last update reported by Lee and
colleagues [1], the global incidence of traumatic spinal cord
injuries (SCI) was estimated in 2007 at 23 cases per million
worldwide. Reported SCI cases mainly concern young
adult men, for the most part victims from motor vehicle
accidents and falls [2]. Cervical and lumbar spines are the
most commonly affected regions, inducing respectively
tetraplegia and paraplegia. Patients suffer from motor im-
pairments, spasticity, neuropathic pain, reflexive, sphincter,
sexual and sensitive troubles, accompanied by highly disab-
ling financial and social issues. Although experimental and
clinical research have provided significant improvements
in medical management and clinical recuperation after SCI
in the last decade, no treatment allows complete functional
recovery of patients, whatever the considered therapeutic
strategy.
The development of such efficient treatments should
first be based on the complete understanding of SCI phys-
iopathological events. Those events are gathered in three
major phases (acute, sub-acute and chronic), as previously* Correspondence: s.wislet@ulg.ac.be
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unless otherwise stated.reviewed [3,4]. Briefly, 1) the acute phase events after trau-
matic SCI and spinal shock encompass axonal disruption
and neuronal death, blood supply default and ischemia,
edema, invasion of granulocytes, disruption in ionic bal-
ance and neurotransmitter release; 2) the sub-acute (inter-
mediate) stage starts around 7 days after the lesion and is
characterized by further oxidative stress taking place by
lipid peroxidation and free-radical production, as well as
by the recruitment of macrophages and lymphocytes,
which secrete cytokines and promote the development of
an inflammatory environment; 3) the chronic phase arises
after a few weeks to months, encompassing continuous
alteration of ionic balance, apoptosis of oligodendrocytes
and consequent demyelination, cavities and astroglial scar
formation, persisting for years. Overall, those unfavorable
events hamper axonal regrowth and functional recovery.
Accordingly, administration of high doses of methyl-
prednisolone in the first hours after SCI was shown to
reduce lesion extent and to limit motor decline in patients
[5]. Up to now, corticosteroid administration remains the
most efficient attempt to cure SCI patients by counterac-
ting the inflammatory reaction. However, no complete
regeneration can be achieved despite great advances, and
thus, the fine-tuning of the inflammatory reaction should
be more precisely considered.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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after SCI largely contributes to the elaboration of un-
favorable tissue environment. Paradoxically, several stu-
dies pointed out that the inflammatory reaction could be
mandatory in order to initiate efficient tissue repair [6].
Basically, early inflammatory events involve sequential
recruitment of three main types of peripheral immune
cells: 1) neutrophils are the first inflammatory cells to
arrive at the site of injury, with a peak at 24 hours post-
injury. Those cells phagocyte and clear debris, secrete
proteases, elastase, myeloperoxidase and release reactive
oxygen species (ROS); 2) circulating monocytes/macro-
phages are subsequently recruited (peak at 7 days post-
injury), release cytokines such as TNF-α, IL-1β, nitric
oxide, prostaglandins and leukotrienes, and also exert
important phagocytic abilities; 3) lymphocytes progres-
sively invade the lesion site, concomitantly to macrophages
and secrete cytokines in the lesion epicenter. However, the
number of recruited lymphocytes remains low compared
to other cell types [7-9] (Figure 1).
Noteworthy, microglial cells of the spinal cord tissue
contribute to the inflammatory reaction as well (reviewed
in [10]), even if the distinction between those resident
macrophages and peripheral blood-derived macrophages
is still difficult to establish and their respective roles in
SCI remain under investigation. Indeed, it appears that
microgliocytes and peripheral monocytes differentially con-
tribute to SCI recovery [11], and present distinct time-
frames of action and phagocytic activities [12].
Macrophages have been the most studied immune
cells in the context of spinal cord inflammation for
many years and are now considered as crucial for
tissue repair and functional recovery [13,14]. Exciting
experimental results even led to clinical application of
autologous macrophage-based therapies for SCI, even if
further investigations are needed to characterize the
significant effect of such interventions [15,16].Figure 1 Global temporal sequence of leukocyte recruitment of the sNonetheless, scientists kept on delineating the mecha-
nisms by which monocytes/macrophages were acting in
the spinal cord after traumatic injuries. Two subtypes of
macrophages were recently identified and classified as
classically activated M1 macrophages, and alternatively
activated M2 macrophages. Basically, M1 macrophages
secrete IL-1β, TNFα and ROS, promoting tissue destruc-
tion and killing of parasites, whereas M2 macrophages
secrete IL-10, IL-1RA or chemokines and induce tissue re-
modeling [17,18]. Both of those subtypes exert contrasting
immunomodulatory actions in pathological conditions
and especially in SCI [19,20]. Therefore, it appears that
M2 macrophages are of great interest with regard to SCI
therapy, as recently reviewed [21].
Altogether, existing evidence reveals that scientists
reach a consensus about the required role of immunity
and inflammation in nervous system disorders, and in
spinal cord injuries in particular, while the understanding
of molecular and cellular mechanisms by which each type
of immune cells is acting is still under progress. However,
as inflammation essentially implies sequential recruitment
and activation of neutrophils and macrophages, it is sur-
prising to note that the roles of the former are quite less
known compared to the roles of the latter. Therefore, in
this review, we will gather information about neutrophils
and detail what is known about the different actions they
could exert in the damaged nervous tissue, in an effort to
reconsider the controversial role of those intriguing cells
in spinal cord traumatic lesions.Neutrophils - origin, identification and general
role in inflammatory response
Granulocytes are a subset of white blood cells charac-
terized by their polylobulated nucleus and by their
cytoplasmic granules, which are differentially identified
by cytological stainings and allow distinction betweenpinal cord after injury in rodents. (Adapted from [6]).
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ulocytes arise from granulo-monocytic progenitors in
the bone marrow (Figure 2). Primary cell fate determi-
nants of the granulocytic and monocytic lineages are
transcription factors PU.1 and C/EBPα. High levels of
PU.1 promote a macrophage differentiation program
through the secondary determinants Egr1,2/Nab-2, while
repressing neutrophil-specific genes. Conversely, elevated
levels of C/EBPα and secondary GFi-1 induce granulo-
cytic differentiation, while antagonizing monocyte de-
velopment (as reviewed by [22,23]). Primary granules
appear at the promyelocyte stage and contain microbi-
cidal proteins and acid hydrolases such as myeloperoxi-
dase and lysozyme. Promyelocytes then develop into
myelocytes, which display secondary or specific granules
of neutrophilic, eosinophilic or basophilic cytochemical
characteristics, and contain other hydrolases and chemo-
tactic factors. Tertiary granules include secretory vesiclesFigure 2 Schematic view of granulopoiesis and neutrophil terminal d
myeloid progenitor; GMP, granulocyte/monocyte progenitor; GP, granulocy
erythroid progenitor; MP, monocyte/macrophage progenitor; NK, natural kicontaining plasma proteins, and gelatinase granules.
While primary granules are discharged exclusively into
phagosomes, secondary and tertiary granules are released
both outside the cell and in the extracellular medium.
A network of hematopoietic growth factors and cytokines
(for example, granulocyte colony-stimulating factor (G-
CSF)) regulates the production of granulocytic cells. G-CSF
is a major regulator of neutrophilic granulocyte production
and modulates the proliferation, survival, maturation and
functional activation of these cells [24]. By activating the
release of proteases from granulocytes, G-CSF induces a
massive egress of immature cells from the bone marrow,
including hematopoietic and non-hematopoietic stem cells,
as well as granulocytic progenitors and precursors [25].
During bacterial infection or traumatic lesion, neutro-
phils are recruited from the bloodstream and migrate
across endothelial barriers to reach the inflammatory site,
being highly sensitive to chemoattractant signals such asifferentiation. CLP, common lymphoid progenitor; CMP, common
te progenitor); HSC, hematopoietic stem cell; MEP, megakaryocyte/
ller.
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the CXCL12-CXCR4 or CXCL1/2-CXCR2 signalization
pathways also regulate neutrophil mobilization and activa-
tion in inflammatory conditions, including in nervous
system disorders [26-30]. Once recruited at their site of
action, neutrophils roll and adhere to endothelial barriers
before crossing over; they reach the lesion and secrete
cytokines, release their cytoplasmic secondary and tertiary
granule content, phagocyte cell debris, and form neutro-
phil extracellular traps [31], altogether clearing the le-
sioned tissue and/or microbes in a complex network of
pathways. Cellular and molecular details concerning re-
cruitment and activity of neutrophils in health and disease
are reviewed in depth in [32,33].
Granulocytes are specifically identified by the expression
of surface antigens CD66b and CD11b/c, which are re-
sponsible for adhesion and cell-cell interaction; and CD13,
CD16 or CD88 (among others) mediating different aspects
of the immune response. Murine granulocytes also ex-
press Ly6g and Ly6C members of the Ly6 family, poten-
tially involved in neutrophil recruitment and migration
[34]. These markers are often used for leukocyte subset
identification and targeted in antibody-mediated depletion
strategies [34,35], providing numerous insights into neu-
trophil biological function in a wide panel of domains.Neutrophil implication in spinal cord injuries
Neutrophils are usually considered as the “bad guys”,
bluntly accumulating in the inflammatory core of a tissue
lesion, secreting proteases, oxidative and tissue-degrading
enzymes, thus elaborating a harmful tissue environment.
Likewise, most of the studies describe them as detrimental
actors. More specifically, neutrophils have been described
to promote neurotoxicity on dorsal root ganglia neurons
via the activity of matrix metalloproteinase 9, generation
of ROS and secretion of TNF-α [36]. Cell-cell contact
between neutrophils and neurons also seem to generate
cytotoxicity [37].
Very few papers have focused on the role of neutro-
phils in SCI models, but their detrimental action was
mainly highlighted as an effect/consequence of other
treatments and conditions. Indeed, in most conditions, a
lower neutrophil accumulation in the lesion was associ-
ated with reduced pro-inflammatory cytokines, reduced
apoptosis and oxidative stress and significant motor re-
covery (see Additional file 1: Table S1). Besides underlin-
ing the deleterious effect of neutrophils, these studies
also provided clues about the different ways in which
these cells are recruited in the injured tissue. For instance,
it was shown that neutrophil infiltration in the damaged
spinal cord was reduced after blocking the leukotriene B4/
BLT1 receptor signaling [38], after inhibiting phospho-
diesterase 4 [39] or in absence of myeloperoxidase [40].The role of the NF-κB signaling pathway was sug-
gested, both in neutrophil invasion and in neutrophil
activity in the lesion. Indeed, the blockade of inhibitor of
NF-κB kinase subunit β (IKKβ) neutralized the secretion of
CXCL1 and the subsequent neutrophil infiltration, but also
the expression of pro-inflammatory genes, simultaneously
improving tissue preservation and motor function [41].
Together with the chemokines CCL2 and CXCL2,
CXCL1 was proposed as a neutrophil chemoattractant,
which would be secreted by spinal cord astrocytes under
IL-1 receptor (IL-1R)/MyD88 signalization [42], and
which even seemed to mediate neuropathic pain [43].
Consistently, the concentration of CXCL1 in the serum
of SCI patients is increased in the first week following
injury, compared to healthy patients [44].
All these results essentially classify neutrophils as un-
favorable actors in the inflammatory response, still it ap-
pears that their roles in injury/repair processes need to be
more specifically addressed. Indeed, as clearly depicted in
Additional file 1: Table S1, the specific activity of neutro-
phils in the spinal cord is largely unknown. There is
now increasing evidence that neutrophils also exert at
least indirect beneficial effects, probably by initiating
inflammation-associated tissue repair, thus prompting
us to re-evaluate and nuance the beneficial/harmful
role of neutrophils in the injured spinal cord.
Recent specific antibody-based methods of Ly6G/Gr-1+
neutrophil depletion [34,45] revealed that the presence of
neutrophils unexpectedly reduced the levels of ROS in a
spinal cord lesion [46]. Surprisingly, Stirling and col-
leagues showed that the depletion of Ly6G/Gr-1+ neutro-
phils impaired the functional outcome in SCI mice, by
preventing early vascular recruitment, rolling and adhe-
sion to endothelia, spinal cord tissue infiltration, and ex-
acerbating CXCL1, CCL2, G-CSF and CCL9 production
inside the spinal cord as a compensatory attempt [47].
This study definitively demonstrated, for the first time,
that neutrophils were required for appropriate inflamma-
tory reaction and subsequent tissue repair after SCI. A few
months later it was shown that secreted leukocyte prote-
ase inhibitor (SLPI) was required for SCI recovery. SLPI is
secreted by neutrophils and astrocytes in the spinal cord
tissue [48], which highlights a hypothetical mechanism
underlying positive neutrophil action. On the other hand,
neutrophils accumulate in the injured spinal cord of mice
lacking tenascin-C, while axonal fibers penetrate easier
through the spinal cord tissue [49], suggesting that neu-
trophils could contribute to the elaboration of a suitable
environment for axonal regeneration.Neutrophils in other nervous system disorders
Neutrophils [50] and oxidative stress [51] are frequently
associated with the pathogenesis of Alzheimer’s disease
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several studies suggested that the number and function
of circulating neutrophils were reduced in AD patients
[52-54] as a consequence of the disease. New insights in
the physiopathological processes of AD showed that
neutrophils migrate towards amyloid plaques, maybe
suggesting a potential interaction worthy of thorough
characterization [55] in order to specify the role of neu-
trophils in AD pathogenesis.
It is also well accepted that neutrophils are a key player
of the regulatory sequence of experimental autoimmune
encephalomyelitis (EAE), essentially recruited and activated
by inflammatory chemokines such as CXCL1, CXCL2 or
CCL2 [56-58]. They are also involved in blood brain bar-
rier disruption during the onset of experimental auto-
immune encephalomyelitis in mice, probably because of
an increased IL-1R-dependent transmigration ability [59].
Despite the demonstration of the numerous detri-
mental consequences associated with neutrophils, there
is a noticeable gap of knowledge about how neutrophils
are properly working in brain and spinal cord injuries.
Noteworthy, recently published data now tend to re-
verse the trend and suggest that the role of neutrophils
could be more balanced than it seems. Whereas the
contribution of neutrophils to tissue repair and reco-
very from experimental stroke was highlighted several
years ago (as reviewed in [60]), recently published re-
sults addressed the specific impact of neutrophils in
inflammation-induced regeneration of the optic nerve
and in peripheral nerve regeneration (Additional file 1:
Table S1). Indeed, Yin and colleagues demonstrated
that neutrophils are recruited during the first three days
after zymosan-induced optic nerve inflammation, and
secrete high levels of oncomodulin. Interestingly, macro-
phages that reach the lesion later on also secrete oncomo-
dulin. Oncomodulin is a 12-kDa calcium-binding protein,
which is secreted by neutrophils and macrophages, and
was previously demonstrated to support neural regene-
ration in retinal ganglion cells in culture [61] and in the
optic nerve [62]. However, macrophages alone are not
sufficient to induce regeneration in the optic nerve when
neutrophil recruitment is specifically prevented [63], sug-
gesting an essential role for neutrophils and their specific
oncomodulin secretion inside the optic nerve.
Neutrophils have been designated as responsible for
hypersensitivity/neuropathic pain occurring after periph-
eral nerve injury [64,65]. Once again, however, several
observations suggest a role for neutrophils in peripheral
nerve regeneration. It has been shown that axonal re-
growth after peripheral nerve injury was abolished in the
absence of myeloid cells, which are specifically required
to clear myelin debris and secrete neurotrophic factors
such as neurotrophin-3,4,5 and brain-derived neuro-
trophic factor. Interestingly, it seemed that spinal cordaxons needed myeloid cell support as well to properly
regenerate in a peripheral nerve graft [66].
Granulocyte colony-stimulating factor: its
implication in experimental spinal cord injury,
and clinical data
G-CSF is an important regulating factor of neutrophil
development, recruitment and activity in physiological
and pathological conditions. As stated below, G-CSF is
largely described in SCI experimental models and in
clinical trials because of its plenty of properties, both on
the hematological and neurological points of view. Im-
portantly, a hypothetic G-CSF-dependent role of neutro-
phils in SCI would be worth considering. Details about
G-CSF activity in SCI are therefore of significant interest
in order to further define the precise aspects of the
inflammatory response after lesion.
Fundamentally, G-CSF is a 19,6-kDa glycoprotein [67]
that binds on a specific G-CSF receptor at the surface of
hematopoietic stem cells from the bone marrow, pro-
moting their proliferation and differentiation into granu-
locytes, which are further released in the peripheral
bloodstream. G-CSF also modulates mature neutrophil
proliferation, activation and recruitment, therefore play-
ing a pivotal role in the regulation of inflammatory re-
sponses. G-CSF induces mobilization of bone marrow
stem cells into the peripheral blood through an indirect
mechanism involving degradation of adhesion molecules
by proteases released from activated neutrophils [68].
On the other hand, it has been shown that G-CSF recep-
tor was also expressed by neurons of the central nervous
system, and that G-CSF has neurotrophic actions via
anti-apoptotic, anti-excitotoxic and pro-neurogenic abil-
ities [69] as particularly addressed in models of cerebral
ischemia [70,71], amyotrophic lateral sclerosis [72,73] or
in the study of memory and cognitive functions [74].
Therefore, besides being extensively used in the clinic to
counteract chemotherapy-associated neutropenia [75]
and collect hematopoietic stem cells by apheresis [76],
G-CSF was also proposed as a therapeutic option for the
treatment of SCI. Indeed, Japanese researchers recently
applied G-CSF as a clinical treatment for patients suffer-
ing from SCI. Modest but non-negligible motor and sen-
sory improvements were observed, whereas no adverse
effects were reported [77-79], suggesting a potential
beneficial effect of G-CSF in the therapy of SCI.
Different studies have already evidenced the beneficial
effects of G-CSF in experimental models of SCI [80,81],
which seem to be mainly associated with the prevention
of excitotoxicity and apoptotic neuronal death, through
several possible mechanisms [82]. G-CSF upregulates
chaperone proteins, such as nucleophosmin-1 in moto-
neurons after spinal cord hemisection [83], reduces mye-
loperoxidase activity and lipid peroxidation [84] and
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vascular endothelial growth factor A expression in glial
cells after spinal cord ischemia [85]. It also appears that
G-CSF-associated neuroprotection, through its mobilization
capacity, is equivalent to bone marrow mononuclear
stem cell-induced neuroprotection [86]. Besides acting
on neural cells, G-CSF also modulates inflammatory
reaction and immune cell recruitment and activation
in the injured spinal cord. Recent data showed that G-
CSF induces alternative activation of microglial macro-
phages, thus promoting tissue repair [87]. Combined
with stem cell factor administration, G-CSF increases
the number of activated microglial cells and oligoden-
drocytes [88], whilst saving oligodendrocytes from
SCI-induced cell death by reducing IL-1β and TNF-α
and up-regulating the anti-apoptotic protein Bcl-xL
[89]. Additional data are now required to elucidate a
putative intermediate role of neutrophils in G-CSF-
mediated effects on SCI.
Conclusions
Although the prevalent view emerging from the current
literature depicts neutrophils in SCI as cells with harm-
ful actions and effects, recent data strongly suggest that
their inflammatory function could oppositely provide
valuable outcome for tissue repair. Indeed, it appears
that neutrophils have always been classically considered
as damaging despite the lack of knowledge on their pre-
cise mechanisms of actions after SCI. While neutrophils
have their own activity by secreting enzymes or other
molecules, their fine interactions with other immune
cells (for example, macrophages) may accurately guide the
inflammatory process as well. Neutrophils are important
inducers of the inflammatory sequence, as observed in
models of rheumatoid arthritis [90], antibody-mediated in-
flammation [91], or acute respiratory distress syndrome
[92]. Indeed, neutrophils set the stage for macrophages
which phagocyte debris and clean the lesioned tissue, in
different inflammatory conditions such as bacterial infec-
tion [93,94] or physical exercise [95], among others. Be-
sides, neutrophils also interact with T lymphocytes and
natural killer cells, as recently reviewed [96]. It has also
been demonstrated that neutrophils can promote wound
repair by releasing angiogenic factors such as IL-8 or vas-
cular endothelial growth factor, and then inducing neovas-
cularization, which is crucial for inflammation-mediated
tissue remodeling [97,98].
In addition, neutrophil-induced positive effects could
also be linked to intrinsic properties of sub-populations.
As described in several types of cancers, tumor-associated
neutrophils are classified according to their pro- or antitu-
moral global actions as N1 (pro-tumor) and N2 (anti-
tumor) [99]. As no phenotypic analysis of neutrophils has
ever been carried out in traumatic lesions of the nervoussystem, one can imagine that the same duality could be
translated, just as it is the case for the M1/M2 macro-
phage dyad (see above).
Overall, the lack of knowledge about the proper role of
neutrophils in SCI and repair now becomes blindingly ob-
vious. Neutrophils have usually been considered as dele-
terious actors to target for reducing lesion extent; however,
it is now clear that their role must be thoroughly ques-
tioned. Further information about their cellular and mo-
lecular mechanisms of action should provide new insights
in the field of SCI, and also in neurological diseases in
general.
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